research

HLA-Bw4-I-80 isoform differentially influences clinical outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 isoforms in rituximab or dinutuximab-based cancer immunotherapy

Authors
Publication date
1 January 2017
Publisher
Digital Commons@Becker
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Digital Commons@Becker

      redirect
      oaioai:digitalcommons.wustl.edu:o...
      Last time updated on 14/08/2017